Fisher Adds GenTel® Thin-Film Nitrocellulose Slides to Its Portfolio
News Oct 27, 2005
Pierce Biotechnology, a unit of Fisher Biosciences, has contracted with GenTel BioSurfaces of Madison, Wis., to distribute GenTel’s PATH™ brand thin-film nitrocellulose slides and has licensed the use of GenTel technology in developing protein arrays for life-science research and drug discovery.
GenTel slides are designed for protein-array applications, including the profiling of disease biomarkers to improve the safety and efficacy of drugs.
GenTel applies an ultra-thin nitrocellulose film to a standard 3" x 1" glass slide. This film is 50 times thinner than conventional nitrocellulose slides and offers significant improvements over traditional glass slides.
“These slides have higher binding capacity than traditional glass slides and lower background fluorescence than traditional nitrocellulose slides,” said Leland Foster, chief executive officer of Fisher Biosciences.
“The combination of higher capacity and lower background fluorescence results in increased sensitivity with fluorescent-detection systems.” In addition, GenTel slides are compatible with Pierce chemiluminescent-detection systems.
“We believe our relationship with Pierce is a perfect fit and in line with our business plan and core business of multiplex immunoassays. This agreement marks a significant milestone for GenTel since it will help us access the life-science markets,” said Dr. Robert Negm, vice president of business development at GenTel.
In developing products with GenTel technology, Pierce will focus initially on building on its existing SearchLight® multiplex protein-profiling systems.
These products will offer efficiency for customers conducting microarrays, whether in academic research or drug discovery.
Microarray systems using GenTel technology enable researchers to simultaneously measure the expression of up to 25 proteins in one experiment. This can be particularly valuable to researchers using siRNA to map protein pathways.
“The combination of slide-based arrays with our existing SearchLight products will provide seamless integration for customers who want to migrate from low- to high-throughput assays,” said Foster.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE